Icotinib or Whole Brain Irradiation in EGFR-mutant Lung Cancer
Status:
Completed
Trial end date:
2016-09-14
Target enrollment:
Participant gender:
Summary
EGFR-TKI is good for the patients with EGFR-mutant non-small cell lung cancer.We design this
clinical trail to confirm if the efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase
Inhibitor(EGFR-TKI )(ICOTINIB) is better than whole brain irradiation for the patient with
EGFR-mutant non-small cell lung cancer.
Phase:
Phase 3
Details
Lead Sponsor:
Guangdong Association of Clinical Trials
Collaborators:
Guangdong General Hospital Guangdong Provincial People's Hospital